P. Schauerte et al., Catheter stimulation of cardiac parasympathetic nerves in humans - A novelapproach to the cardiac autonomic nervous system, CIRCULATION, 104(20), 2001, pp. 2430-2435
Citations number
22
Categorie Soggetti
Cardiovascular & Respiratory Systems","Cardiovascular & Hematology Research
Background-Cardiac parasympathetic nerves run alongside the superior vena c
ava (SVC) and accumulate particularly epicardially adjacent to the orifice
of the coronary sinus (CS). In animals, these nerves can be electrically st
imulated inside the SVC or CS, which results in negative chronotropic/dromo
tropic effects and negative inotropic effects in the atria but not the vent
ricles. Parasympathetic nerve stimulation (PS) with 20 Hz in the CS, howeve
r, also excites the atria, thereby inducing atrial fibrillation, The presen
t study overcomes this limitation by applying high-frequency nerve stimuli
within the atrial refractory period. Using this technique, we investigated
for the first time whether neurophysiological effects similar to those in a
nimals can be obtained in humans.
Methods and Results-In 25 patients, parasympathetic nerves were stimulated
via a multipolar electrode catheter placed in the SVC (stimulation with 20
Hz; n=14) or CS (pulsed 200-Hz stimuli; n=11). A significant sinus rate dec
rease and prolongation of the antegrade Wenckebach period was achieved duri
ng PS in the SVC. During PS in the CS, a graded-response prolongation of th
e antegrade Wenckebach interval was observed with increasing PS voltage unt
il third-degree AV block occurred in 8 of 11 patients. The negative chronot
ropic/dromotropic effects started and terminated immediately after the onse
t and termination of PS, respectively. Atropine abolished these effects (n=
11).
Conclusions-Human parasympathetic efferent nerve stimulation induces revers
ible negative chronotropic and dromotropic effects. PS may serve as an adju
nctive tool for the diagnosis/treatment of supraventricular tachycardias an
d may be beneficial for ventricular rate slowing during tachycardic atrial
fibrillation in patients with congestive heart failure.